About Ole Frølich

This author has not yet filled in any details.
So far Ole Frølich has created 29 blog entries.

Pharming Reports On Preliminary Financial Results 2014

2017-05-31T19:25:13+01:00March 5, 2015|HAEi News|

Pharming Group N.V. has published its preliminary (unaudited) financial results for the year ended 31 December 2014. From the financial highlights: Revenues from operations increased to 21.2 million EUR (2013: 6.8 million EUR) as a result of higher license fees, including the receipt of a 20.0 million USD (16 million EUR) milestone from US partner [...]

Last newsletter of 2014 out now

2017-05-31T19:25:13+01:00December 23, 2014|HAEi News|

The 6th edition of the HAEi newsletter in 2014 has the following topics: Executive Committee Meeting, fall 2014; New and upcoming national patient groups; Trails recruiting patients; News from our national member organizations; News from our national patient groups; Global advocacy work; New papers on HAE; News from the industry; HAEi around the globe. We [...]

BioCryst initiates OPuS-2: A clinical trial of BCX4161 in HAE-patients

2017-05-31T19:25:13+01:00December 18, 2014|HAEi News|

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX4161 in patients with HAE. OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of BCX4161, 300 mg and 500 mg, administered [...]

BioCryst Reports Third Quarter 2014 Financial Results

2017-05-31T19:25:13+01:00November 6, 2014|HAEi News|

BioCryst Pharmaceuticals has announced financial results for the third quarter ended September 30, 2014. Extracts from the report: "The primary focus continues to be our oral kallikrein inhibitor program for HAE. Preparations are underway for our OPuS-2 clinical trial of BCX4161 and we expect to begin enrolling HAE patients before year end. We continue to [...]